Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

TICAGRELOR

5 Limited Use · 5 not a benefit

Other products in the same Health Canada class (B01A, B01AC) — coverage varies; not interchangeable

  • Eptifibatide (Integrilin): not a benefit
  • Apixaban (Eliquis): general benefit
  • Dabigatran etexilate (Pradaxa): general benefit, Not a benefit
  • Edoxaban (Lixiana): general benefit
  • Enoxaparin (Noromby): general benefit
  • Rivaroxaban (Xarelto): general benefit

5 more in the class list below

Apo-Ticagrelor · DIN 02482630 · 90mg · tablet

Limited Use — Reason for Use code 441 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 441 required
Write on scriptLU code 441 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 441
Reason for Use code 441 In combination with low-dose ASA for patients with: - Non-ST elevation acute coronary syndrome (ACS)* (unstable angina or myocardial infarction [MI]); OR - ST-segment elevation myocardial infarction (STEMI); OR - Stent thrombosis while taking clopidogrel plus low-dose ASA. Treatment must be initiated in hospital. Notes: A) *ACS without ST elevation is defined as 2 of 3 of the following criteria: 1. ST-segment changes on electrocardiogram (ECG) indicating ischemia 2. Positive biomarker indicating myocardial necrosis 3. One of the following: - Greater than or equal to 60 years of age - Previous MI or coronary artery bypass graft (CABG) - Coronary artery disease (CAD) with greater than or equal to 50% stenosis in greater than or equal to 2 vessels - Previous ischemic stroke, transient ischemic attack (TIA; hospital-based diagnosis), carotid stenosis (greater than or equal to 50%), or cerebral revascularization - Diabetes mellitus - Peripheral artery disease - Chronic renal dysfunction B) Co-administration of ticagrelor with high maintenance dose ASA (greater than 150mg daily) is not recommended. C) Definite stent thrombosis, according to the Academic Research Consortium, is a total occlusion originating in or within 5 mm of the stent, or is a visible thrombus within the stent, or is within 5 mm of the stent in the presence of an acute ischemic clinical syndrome within 48 hours. Definite stent thrombosis must be confirmed by angiography or by pathologic confirmation of acute thrombosis. D) Ticagrelor is contraindicated in patients with active pathological bleeding, in those with a history of intracranial hemorrhage and moderate to severe hepatic impairment. Coverage limit: LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Ticagrelor · DIN 02482630 Manufacturer: Apotex Inc.; listing date 2023-01-31 Health Canada: Marketed since 2022-12-14 · brand APO-TICAGRELOR · ATC B01AC24 TICAGRELOR · form Tablet · route Oral · ingredients TICAGRELOR 90 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Ticagrelor: Formulary list price $0.3960/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3960 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97306 · Verify on the e-Formulary ↗ (DIN 02482630)

Source record
DIN 02482630: Apo-Ticagrelor Raw flags: sec12=Y, sec3=Y Item: 201200088; group id 261; item number 0511; lccId 00230; manufacturer id APX Source form: Tab; strength: 90mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.3960; ministry $0.3960 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02482630 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97306
Interchangeable products
Brilinta · DIN 02368544 · $0.3960 Jamp Ticagrelor · DIN 02531801 · $0.3960 M-Ticagrelor · DIN 02529769 · $0.3960 Taro-Ticagrelor · DIN 02492598 · $0.3960
Shortage status: shortage reported ended 2026-07-23 (report last updated 2026-07-23); confirm supply with the pharmacy; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02482630
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Brilinta · DIN 02368544 · 90mg · tablet

Limited Use — Reason for Use code 441 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 441 required
Write on scriptLU code 441 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 441
Reason for Use code 441 In combination with low-dose ASA for patients with: - Non-ST elevation acute coronary syndrome (ACS)* (unstable angina or myocardial infarction [MI]); OR - ST-segment elevation myocardial infarction (STEMI); OR - Stent thrombosis while taking clopidogrel plus low-dose ASA. Treatment must be initiated in hospital. Notes: A) *ACS without ST elevation is defined as 2 of 3 of the following criteria: 1. ST-segment changes on electrocardiogram (ECG) indicating ischemia 2. Positive biomarker indicating myocardial necrosis 3. One of the following: - Greater than or equal to 60 years of age - Previous MI or coronary artery bypass graft (CABG) - Coronary artery disease (CAD) with greater than or equal to 50% stenosis in greater than or equal to 2 vessels - Previous ischemic stroke, transient ischemic attack (TIA; hospital-based diagnosis), carotid stenosis (greater than or equal to 50%), or cerebral revascularization - Diabetes mellitus - Peripheral artery disease - Chronic renal dysfunction B) Co-administration of ticagrelor with high maintenance dose ASA (greater than 150mg daily) is not recommended. C) Definite stent thrombosis, according to the Academic Research Consortium, is a total occlusion originating in or within 5 mm of the stent, or is a visible thrombus within the stent, or is within 5 mm of the stent in the presence of an acute ischemic clinical syndrome within 48 hours. Definite stent thrombosis must be confirmed by angiography or by pathologic confirmation of acute thrombosis. D) Ticagrelor is contraindicated in patients with active pathological bleeding, in those with a history of intracranial hemorrhage and moderate to severe hepatic impairment. Coverage limit: LU Authorization Period: 1 year
Savings card: innoviCares lists Brilinta (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)
Savings card: RxHelp ONE lists BRILINTA (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
Limit of one Prescription Drug Card Program / Patient Financial Assistance Card from any adjudicator per DIN and claim submitted. The RxHelpONE card CANNOT be combined with any other card or offer. (Terms of Use) (rxhelp.ca, Sep 10, 2026 ↗)
1 brand, same coverage
Brilinta · DIN 02368544 Manufacturer: AstraZeneca; listing date 2013-04-30 Health Canada: Marketed since 2011-06-01 · brand BRILINTA · ATC B01AC24 TICAGRELOR · form Tablet · route Oral · ingredients TICAGRELOR 90 MG · company Astrazeneca canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.3960 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85352 · Verify on the e-Formulary ↗ (DIN 02368544)

Source record
DIN 02368544: Brilinta Raw flags: sec12=Y, sec3=Y Item: 201200088; group id 261; item number 0511; lccId 00230; manufacturer id AZC Source form: Tab; strength: 90mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $1.8187; ministry $0.3960 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02368544 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85352
Interchangeable products
Apo-Ticagrelor · DIN 02482630 · $0.3960 Jamp Ticagrelor · DIN 02531801 · $0.3960 M-Ticagrelor · DIN 02529769 · $0.3960 Taro-Ticagrelor · DIN 02492598 · $0.3960
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02368544
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp Ticagrelor · DIN 02531801 · 90mg · tablet

Limited Use — Reason for Use code 441 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 441 required
Write on scriptLU code 441 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 441
Reason for Use code 441 In combination with low-dose ASA for patients with: - Non-ST elevation acute coronary syndrome (ACS)* (unstable angina or myocardial infarction [MI]); OR - ST-segment elevation myocardial infarction (STEMI); OR - Stent thrombosis while taking clopidogrel plus low-dose ASA. Treatment must be initiated in hospital. Notes: A) *ACS without ST elevation is defined as 2 of 3 of the following criteria: 1. ST-segment changes on electrocardiogram (ECG) indicating ischemia 2. Positive biomarker indicating myocardial necrosis 3. One of the following: - Greater than or equal to 60 years of age - Previous MI or coronary artery bypass graft (CABG) - Coronary artery disease (CAD) with greater than or equal to 50% stenosis in greater than or equal to 2 vessels - Previous ischemic stroke, transient ischemic attack (TIA; hospital-based diagnosis), carotid stenosis (greater than or equal to 50%), or cerebral revascularization - Diabetes mellitus - Peripheral artery disease - Chronic renal dysfunction B) Co-administration of ticagrelor with high maintenance dose ASA (greater than 150mg daily) is not recommended. C) Definite stent thrombosis, according to the Academic Research Consortium, is a total occlusion originating in or within 5 mm of the stent, or is a visible thrombus within the stent, or is within 5 mm of the stent in the presence of an acute ischemic clinical syndrome within 48 hours. Definite stent thrombosis must be confirmed by angiography or by pathologic confirmation of acute thrombosis. D) Ticagrelor is contraindicated in patients with active pathological bleeding, in those with a history of intracranial hemorrhage and moderate to severe hepatic impairment. Coverage limit: LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp Ticagrelor · DIN 02531801 Manufacturer: Jamp Pharma Corporation; listing date 2024-05-31 Health Canada: Marketed since 2024-03-28 · brand JAMP TICAGRELOR · ATC B01AC24 TICAGRELOR · form Tablet · route Oral · ingredients TICAGRELOR 90 MG · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Jamp Ticagrelor: Formulary list price $0.3960/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3960 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102090 · Verify on the e-Formulary ↗ (DIN 02531801)

Source record
DIN 02531801: Jamp Ticagrelor Raw flags: sec12=Y, sec3=Y Item: 201200088; group id 261; item number 0511; lccId 00230; manufacturer id JPC Source form: Tab; strength: 90mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.3960; ministry $0.3960 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02531801 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102090
Interchangeable products
Apo-Ticagrelor · DIN 02482630 · $0.3960 Brilinta · DIN 02368544 · $0.3960 M-Ticagrelor · DIN 02529769 · $0.3960 Taro-Ticagrelor · DIN 02492598 · $0.3960
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02531801
Shortage record checked 2026-09-13T08:10:21.292534+00:00

M-Ticagrelor · DIN 02529769 · 90mg · tablet

Limited Use — Reason for Use code 441 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 441 required
Write on scriptLU code 441 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 441
Reason for Use code 441 In combination with low-dose ASA for patients with: - Non-ST elevation acute coronary syndrome (ACS)* (unstable angina or myocardial infarction [MI]); OR - ST-segment elevation myocardial infarction (STEMI); OR - Stent thrombosis while taking clopidogrel plus low-dose ASA. Treatment must be initiated in hospital. Notes: A) *ACS without ST elevation is defined as 2 of 3 of the following criteria: 1. ST-segment changes on electrocardiogram (ECG) indicating ischemia 2. Positive biomarker indicating myocardial necrosis 3. One of the following: - Greater than or equal to 60 years of age - Previous MI or coronary artery bypass graft (CABG) - Coronary artery disease (CAD) with greater than or equal to 50% stenosis in greater than or equal to 2 vessels - Previous ischemic stroke, transient ischemic attack (TIA; hospital-based diagnosis), carotid stenosis (greater than or equal to 50%), or cerebral revascularization - Diabetes mellitus - Peripheral artery disease - Chronic renal dysfunction B) Co-administration of ticagrelor with high maintenance dose ASA (greater than 150mg daily) is not recommended. C) Definite stent thrombosis, according to the Academic Research Consortium, is a total occlusion originating in or within 5 mm of the stent, or is a visible thrombus within the stent, or is within 5 mm of the stent in the presence of an acute ischemic clinical syndrome within 48 hours. Definite stent thrombosis must be confirmed by angiography or by pathologic confirmation of acute thrombosis. D) Ticagrelor is contraindicated in patients with active pathological bleeding, in those with a history of intracranial hemorrhage and moderate to severe hepatic impairment. Coverage limit: LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
M-Ticagrelor · DIN 02529769 Manufacturer: Mantra Pharma Inc.; listing date 2022-12-21 Health Canada: Marketed since 2022-11-11 · brand M-TICAGRELOR · ATC B01AC24 TICAGRELOR · form Tablet · route Oral · ingredients TICAGRELOR 90 MG · company Mantra pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

M-Ticagrelor: Formulary list price $0.3960/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3960 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101900 · Verify on the e-Formulary ↗ (DIN 02529769)

Source record
DIN 02529769: M-Ticagrelor Raw flags: sec12=Y, sec3=Y Item: 201200088; group id 261; item number 0511; lccId 00230; manufacturer id MAT Source form: Tab; strength: 90mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.3960; ministry $0.3960 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02529769 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101900
Interchangeable products
Apo-Ticagrelor · DIN 02482630 · $0.3960 Brilinta · DIN 02368544 · $0.3960 Jamp Ticagrelor · DIN 02531801 · $0.3960 Taro-Ticagrelor · DIN 02492598 · $0.3960
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02529769
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Taro-Ticagrelor · DIN 02492598 · 90mg · tablet

Limited Use — Reason for Use code 441 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 441 required
Write on scriptLU code 441 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 441
Reason for Use code 441 In combination with low-dose ASA for patients with: - Non-ST elevation acute coronary syndrome (ACS)* (unstable angina or myocardial infarction [MI]); OR - ST-segment elevation myocardial infarction (STEMI); OR - Stent thrombosis while taking clopidogrel plus low-dose ASA. Treatment must be initiated in hospital. Notes: A) *ACS without ST elevation is defined as 2 of 3 of the following criteria: 1. ST-segment changes on electrocardiogram (ECG) indicating ischemia 2. Positive biomarker indicating myocardial necrosis 3. One of the following: - Greater than or equal to 60 years of age - Previous MI or coronary artery bypass graft (CABG) - Coronary artery disease (CAD) with greater than or equal to 50% stenosis in greater than or equal to 2 vessels - Previous ischemic stroke, transient ischemic attack (TIA; hospital-based diagnosis), carotid stenosis (greater than or equal to 50%), or cerebral revascularization - Diabetes mellitus - Peripheral artery disease - Chronic renal dysfunction B) Co-administration of ticagrelor with high maintenance dose ASA (greater than 150mg daily) is not recommended. C) Definite stent thrombosis, according to the Academic Research Consortium, is a total occlusion originating in or within 5 mm of the stent, or is a visible thrombus within the stent, or is within 5 mm of the stent in the presence of an acute ischemic clinical syndrome within 48 hours. Definite stent thrombosis must be confirmed by angiography or by pathologic confirmation of acute thrombosis. D) Ticagrelor is contraindicated in patients with active pathological bleeding, in those with a history of intracranial hemorrhage and moderate to severe hepatic impairment. Coverage limit: LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Taro-Ticagrelor · DIN 02492598 Manufacturer: Taro Pharmaceuticals Inc.; listing date 2022-05-31 Health Canada: Marketed since 2022-04-29 · brand TARO-TICAGRELOR · ATC B01AC24 TICAGRELOR · form Tablet · route Oral · ingredients TICAGRELOR 90 MG · company Taro pharmaceuticals inc · schedule Prescription
Check this DIN again · Health Canada product record

Taro-Ticagrelor: Formulary list price $0.3960/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3960 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98259 · Verify on the e-Formulary ↗ (DIN 02492598)

Source record
DIN 02492598: Taro-Ticagrelor Raw flags: sec12=Y, sec3=Y Item: 201200088; group id 261; item number 0511; lccId 00230; manufacturer id TAR Source form: Tab; strength: 90mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.3960; ministry $0.3960 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02492598 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98259
Interchangeable products
Apo-Ticagrelor · DIN 02482630 · $0.3960 Brilinta · DIN 02368544 · $0.3960 Jamp Ticagrelor · DIN 02531801 · $0.3960 M-Ticagrelor · DIN 02529769 · $0.3960
Shortage status: active shortage (reported 2026-04-20, estimated to end 2026-09-11, last updated 2026-08-17); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02492598
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Ticagrelor · DIN 02482622 · 60mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Apo-Ticagrelor · DIN 02482622 Manufacturer: Apotex Inc.; listing date 2022-12-21 Health Canada: Marketed since 2022-12-22 · brand APO-TICAGRELOR · ATC B01AC24 TICAGRELOR · form Tablet · route Oral · ingredients TICAGRELOR 60 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97305 · Verify on the e-Formulary ↗ (DIN 02482622)

Source record
DIN 02482622: Apo-Ticagrelor Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 201200129; group id 260; item number 0510; lccId None; manufacturer id APX Source form: Tab; strength: 60mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $1.2844; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02482622 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97305
Interchangeable products
Brilinta · DIN 02455005 · not recorded Jamp Ticagrelor · DIN 02531798 · not recorded M-Ticagrelor · DIN 02529750 · not recorded Taro-Ticagrelor · DIN 02492571 · not recorded
Shortage status: active shortage (reported 2026-08-25, estimated to end 2026-09-18, last updated 2026-09-11); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02482622
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Brilinta · DIN 02455005 · 60mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Savings card: innoviCares lists Brilinta (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)
Savings card: RxHelp ONE lists BRILINTA (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
Limit of one Prescription Drug Card Program / Patient Financial Assistance Card from any adjudicator per DIN and claim submitted. The RxHelpONE card CANNOT be combined with any other card or offer. (Terms of Use) (rxhelp.ca, Sep 10, 2026 ↗)
1 brand, same coverage
Brilinta · DIN 02455005 Manufacturer: AstraZeneca; listing date 2022-05-31 Health Canada: Marketed since 2016-06-13 · brand BRILINTA · ATC B01AC24 TICAGRELOR · form Tablet · route Oral · ingredients TICAGRELOR 60 MG · company Astrazeneca canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Brilinta: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94181 · Verify on the e-Formulary ↗ (DIN 02455005)

Source record
DIN 02455005: Brilinta Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 201200129; group id 260; item number 0510; lccId None; manufacturer id AZC Source form: Tab; strength: 60mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02455005 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94181
Interchangeable products
Apo-Ticagrelor · DIN 02482622 · not recorded Jamp Ticagrelor · DIN 02531798 · not recorded M-Ticagrelor · DIN 02529750 · not recorded Taro-Ticagrelor · DIN 02492571 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02455005
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp Ticagrelor · DIN 02531798 · 60mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Jamp Ticagrelor · DIN 02531798 Manufacturer: Jamp Pharma Corporation; listing date 2024-02-29 Health Canada: Marketed since 2024-03-28 · brand JAMP TICAGRELOR · ATC B01AC24 TICAGRELOR · form Tablet · route Oral · ingredients TICAGRELOR 60 MG · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102089 · Verify on the e-Formulary ↗ (DIN 02531798)

Source record
DIN 02531798: Jamp Ticagrelor Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 201200129; group id 260; item number 0510; lccId None; manufacturer id JPC Source form: Tab; strength: 60mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $1.2844; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02531798 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102089
Interchangeable products
Apo-Ticagrelor · DIN 02482622 · not recorded Brilinta · DIN 02455005 · not recorded M-Ticagrelor · DIN 02529750 · not recorded Taro-Ticagrelor · DIN 02492571 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02531798
Shortage record checked 2026-09-13T08:10:21.292534+00:00

M-Ticagrelor · DIN 02529750 · 60mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
M-Ticagrelor · DIN 02529750 Manufacturer: Mantra Pharma Inc.; listing date 2022-12-21 Health Canada: Marketed since 2022-12-20 · brand M-TICAGRELOR · ATC B01AC24 TICAGRELOR · form Tablet · route Oral · ingredients TICAGRELOR 60 MG · company Mantra pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101899 · Verify on the e-Formulary ↗ (DIN 02529750)

Source record
DIN 02529750: M-Ticagrelor Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 201200129; group id 260; item number 0510; lccId None; manufacturer id MAT Source form: Tab; strength: 60mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $1.2844; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02529750 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101899
Interchangeable products
Apo-Ticagrelor · DIN 02482622 · not recorded Brilinta · DIN 02455005 · not recorded Jamp Ticagrelor · DIN 02531798 · not recorded Taro-Ticagrelor · DIN 02492571 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02529750
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Taro-Ticagrelor · DIN 02492571 · 60mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Taro-Ticagrelor · DIN 02492571 Manufacturer: Taro Pharmaceuticals Inc.; listing date 2022-05-31 Health Canada: Marketed since 2022-05-31 · brand TARO-TICAGRELOR · ATC B01AC24 TICAGRELOR · form Tablet · route Oral · ingredients TICAGRELOR 60 MG · company Taro pharmaceuticals inc · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98258 · Verify on the e-Formulary ↗ (DIN 02492571)

Source record
DIN 02492571: Taro-Ticagrelor Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 201200129; group id 260; item number 0510; lccId None; manufacturer id TAR Source form: Tab; strength: 60mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $1.2844; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02492571 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98258
Interchangeable products
Apo-Ticagrelor · DIN 02482622 · not recorded Brilinta · DIN 02455005 · not recorded Jamp Ticagrelor · DIN 02531798 · not recorded M-Ticagrelor · DIN 02529750 · not recorded
Shortage status: resolved shortage (ended 2025-11-28); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02492571
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (20:12 Coagulants and Anti-Coagulants) and how they are covered

Matched class: 20:12 Coagulants and Anti-Coagulants

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: APIXABAN, ENOXAPARIN, RIVAROXABAN Some products covered without a code (check the product listing): DABIGATRAN ETEXILATE, EDOXABAN, WARFARIN 20:12 Coagulants and Anti-Coagulants

EPTIFIBATIDE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 0.75mg/mL, 2mg/mL · 100mL Vial Pk, 10mL Vial Pk

APIXABAN

· 38 products · General benefit · strengths: 2.5mg, 5mg · Tab

DABIGATRAN ETEXILATE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit (2), General benefit (4) · strengths: 75mg, 110mg, 150mg · Cap

ENOXAPARIN

· 37 products · General benefit · strengths: 20mg/0.2mL, 30mg/0.3mL, 40mg/0.4mL, 60mg/0.6mL, 80mg/0.8mL, 120mg/0.8mL, 100mg/mL, 150mg/mL, 300mg/3mL · Inj Sol-0.2mL Pref Syr (Preservative-Free), Inj Sol-0.3mL Pref Syr (Preservative-Free), Inj Sol-0.4mL Pref Syr (Preservative-Free), Inj Sol-0.6mL Pref Syr (Preservative-Free), Inj Sol-0.8mL Pref Syr (Preservative-Free), Inj Sol-1mL Pref Syr (Preservative-Free), Inj Sol-3mL Vial Pk (With Preservative)

RIVAROXABAN

· 48 products · General benefit · strengths: 2.5mg, 10mg, 15mg, 20mg · Tab

WARFARIN

· 23 products · Listed, not a benefit (8), General benefit (14), Off-Formulary Interchangeable, not an ODB benefit (1) · strengths: 1mg, 2mg, 2.5mg, 3mg, 4mg, 5mg, 6mg, 10mg · Tab

DALTEPARIN SODIUM

· 10 products · Limited Use, codes 186, 187, 188, 189 · strengths: 3500IU/0.28mL, 7500IU/0.3mL, 2500IU/0.2mL, 5000IU/0.2mL, 10000IU/0.4mL, 12500IU/0.5mL, 15000IU/0.6mL, 18000IU/0.72mL, 16500IU/0.66mL, 25000IU/mL · Inj Pref Syr, Inj Pref Syr-0.66mL Pk, Multidose 3.8mL Pk

FONDAPARINUX SODIUM

· 4 products · Limited Use, codes 378 (2), Off-Formulary Interchangeable, not an ODB benefit (2) · strengths: 2.5mg/0.5mL, 7.5mg/0.6mL · Inj Sol-Pref Syr 0.5mL Pk (Preservative Free), Inj Sol-Pref Syr 0.6mL Pk (Preservative Free)

NADROPARIN CALCIUM

· 7 products · Limited Use, codes 186, 187, 188, 189 · strengths: 9500IU/mL, 19000IU/mL · Pref Syr-0.3mL Pk, Pref Syr-0.4mL Pk, Pref Syr-0.6mL Pk, Pref Syr-0.8mL Pk, Pref Syr-1.0mL Pk

TINZAPARIN SODIUM

· 11 products · Limited Use, codes 186, 187, 188, 189, 323 · strengths: 2500IU/0.25mL, 8000IU/0.4mL, 12000IU/0.6mL, 16000IU/0.8mL, 3500IU/0.35mL, 4500IU/0.45mL, 10000IU/0.5mL, 14000IU/0.7mL, 18000IU/0.9mL, 10000IU/mL, 20000IU/mL · Inj Pref Syr, Inj-2mL Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 20:12 20:12:04 Direct Factor Xa Inhibitors

EDOXABAN

· 11 products · General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (3), General benefit (8) · strengths: 15mg, 30mg, 60mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 20:12:04 20:12:16 Hemostatics

TRANEXAMIC ACID

· 5 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 500mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 20:12:16
Full class listing Related classes: 20:04 Antianemia Drugs, 20:16 Hematopoietic Agents, 20:24 Hemorrheologic Agents Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1. Indications Acute Coronary Syndrome BRILINTA (ticagrelor tablets), co-administered with low-dose acetylsalicylic acid (ASA: 75-150 mg), is indicated for the secondary prevention of atherothrombotic events in patients with acute coronary syndromes (ACS) (see 14 Clinical Trials). History of Myocardial Infarction (at least one year ago) BRILINTA (ticagrelor tablets), co-administered with low-dose acetylsalicylic acid (ASA: 75-150 mg), is indicated for the secondary prevention of atherothrombotic events in patients with a history of myocardial infarction (MI occurred at least one year ago) and a high risk of developing an atherothrombotic event (see 14 Clinical Trials). Coronary Artery Disease, Type 2 Diabetes Mellitus and History of Percutaneous Coronary Intervention BRILINTA (ticagrelor tablets), co-administered with low-dose acetylsalicylic acid (ASA: 75-150 mg), is indicated to reduce the risk of a first myocardial infarction or stroke in patients with Coronary Artery Disease (CAD), Type 2 Diabetes Mellitus (DM), and a history of percutaneous coronary intervention (PCI), who are also at high risk of developing an atherothrombotic event (see 4 Dosage and Administration, 7 Warni… https://pdf.hres.ca/dpd_pm/00083390.PDF PM date: 2026-02-03 Source product: BRILINTA; DIN 02368544; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Apo-Ticagrelor · DIN 02482630 Shortage status: shortage reported ended 2026-07-23 (report last updated 2026-07-23); confirm supply with the pharmacy; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02482630

Check this DIN again

Taro-Ticagrelor · DIN 02492598 Shortage status: active shortage (reported 2026-04-20, estimated to end 2026-09-11, last updated 2026-08-17); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02492598

Check this DIN again

Apo-Ticagrelor · DIN 02482622 Shortage status: active shortage (reported 2026-08-25, estimated to end 2026-09-18, last updated 2026-09-11); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02482622

Check this DIN again

Other review policies

For Apo-Ticagrelor, Brilinta, Jamp Ticagrelor, M-Ticagrelor, Taro-Ticagrelor: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026